{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cloticasone is a synthetic glucocorticoid corticosteroid, an analog of fluticasone. Cloticasone was discovered by Glaxo in the 1980s and claimed to be useful as an antiinflammation agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04546126: Early Phase 1 Interventional Recruiting Radiotracer
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lividomycin is the antibacterial agent produced by Streptomyces lividus. It is aminoglycoside antibiotic. Lividomycin binds to bacterial ribosomes and inhibits protein synthesis. In vitro development of resistance to lividomycin in P. aeruginosa and M. tuberculosis was much slower than that to kanamycin, but was comparable in Staphylococcus aureus. Lividomycin showed a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli. It was fairly effective for the experimental infection with the kanamycin-resistant strains of E. coli and P. aeruginosa producing the kanamycin-phosphorylating enzyme.
Status:
Investigational
Source:
INN:ursulcholic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ursulcholic acid is a soluble form of ursodeoxycholic acid. It is an anticholinergic agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Cetamolol is a beta adrenergic antagonist with intrinsic sympathomimetic activity, patented by Imperial Chemical Industries Ltd for cardiovascular disease treatment. The average plasma half-life of cetamolol is 6.4 hours in humans and peak serum levels are reached 1 to 2 hours after drug intake; oral doses as low as 10 mg produced significant reductions in exercise-induced tachycardia 24 hours after drug administration. Cetamolol is approximately three times as potent as atenolol in blocking exercise-induced tachycardia.
Status:
Investigational
Source:
NCT00992563: Phase 2 Interventional Completed Age Related Macular Degeneration
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Linifanib (ABT-869) is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families, but has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) does not have a general antiproliferative effect due to its high dose requirement. However, it may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3). Linifanib (ABT-869) was in phase III clinical trial for the treatment of hepatocellular carcinoma, but the study failed to meet the primary end point.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Orbofiban was developed as an orally active glycoprotein IIb/IIIa antagonist. By 2001, this drug had progressed to phase III clinical trials. Unfortunately, was found that orbofiban induced thrombocytopenia and thrombosis. In addition, despite no significant excess risk of intracranial hemorrhage, orbofiban was not effective in preventing ischemic stroke or transient ischemic attack. Besides, the use of this drug had led to an increase in mortality. Based on all these results further development of this drug was discontinued.
Status:
Investigational
Source:
Am J Clin Oncol. Apr 2001;24(2):150-4.: Phase 2 Human clinical trial Completed Prostatic Neoplasms
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Menogaril is a semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin. Biochemical studies indicated that, in comparison to doxorubicin, menogaril is bound weakly to DNA, inhibits RNA synthesis less, and has different cell cycle phase-specific cytotoxicity. Menogaril acts as a cleavable complex-stabilizing topoisomerase II inhibitor. Menogaril has been studied in the treatment of various cancers.
Class (Stereo):
CHEMICAL (ACHIRAL)
Temelastine (also known as SK&F 93944) is a competitive histamine H1-receptor antagonist, which does not penetrate the central nervous system. This drug was studied as an anti-allergic agent. Experiments on animals have shown that the drug was efficacious vs. pharmacologic and antigen-induced bronchoconstriction.
